Research Desk Line-up: Amicus Therapeutics Post Earnings Coverage
LONDON, UK / ACCESSWIRE / November 17, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Sangamo Therapeutics, Inc. (NASDAQ: SGMO), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=SGMO. The Company announced on November 15, 2017, that first patient has been treated in the Phase-1/2 clinical trial (the CHAMPIONS study) evaluating SB-913, an investigational invivo genome editing therapy, for the treatment of patients with mucopolysaccharidosis type II (MPS II). For immediate access to our complimentary reports, including today's coverage, register for free now at:
Discover more of our free reports coverage from other companies within the Biotechnology industry. Pro-TD has currently selected Amicus Therapeutics, Inc. (NASDAQ: FOLD) for due-diligence and potential coverage as the Company announced on November 08, 2017, its financial results for Q3 2017 which ended on September 30, 2017. Tune in to our site to register for a free membership, and be among the early birds that get our report on Amicus Therapeutics when we publish it.
At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on SGMO; also brushing on FOLD. Go directly to your stock of interest and access today's free coverage at:
Sangamo at the Start of a New Frontier of Genomic Medicine
Dr. Sandy Macrae, Chief Executive Officer of Sangamo, stated that for the first time, a patient has received a therapy intended to precisely edit the DNA of cells directly inside the body. Dr. Macrae added that the Company is at the start of a new frontier of genomic medicine.
SB-913 Utilizes Sangamo's ZFN Genome Editing Technology
SB-913 is a genome editing product candidate for the treatment of MPS II, and is designed as a single treatment strategy intended to provide stable, continuous production of the IDS enzyme for the lifetime of the patient. Using Sangamo's zinc finger nuclease (ZFN) genome-editing technology, SB-913 inserts a corrective gene into a precise location in the DNA of liver cells. To restrict editing to liver cells, the ZFNs and the corrective gene are delivered in a single intravenous infusion using AAV vectors that target the liver.
Sangamo Working Closely with FDA and NIH Recombinant DNA Advisory Committee
Ed Conner, M.D., Chief Medical Officer of Sangamo, expressed that the Company has been working closely with the FDA and the NIH Recombinant DNA Advisory Committee to make sure that it is thoroughly and prudently developing this new class of medicines.
FDA Granted Fast Track Designation and Orphan Drug Designation for SB-913
On March 01, 2017, the US Food and Drug Administration (FDA) granted orphan drug designation to SB-913 for the treatment of MPS II. On July 13, 2017, FDA granted Fast Track designation to SB-318 and SB-913, for the treatment of MPS I and MPS II, respectively. Additionally, in February 2017, SB-318 for MPS I and SB-913 for MPS II have also received Rare Pediatric Disease designations from the FDA.
About the CHAMPIONS Study
The CHAMPIONS study is an open-label clinical study designed to assess the safety, tolerability, and preliminary efficacy of the SB-913 investigational genome editing therapy in up to nine adult males with MPS II.
About MPS II
MPS II, also known as Hunter syndrome, is a condition that affects many different parts of the body and occurs almost exclusively in males. MPS II has a wide range of symptoms that vary in severity and can be managed and treated with enzyme replacement therapies, but there is no cure for MPS II. MPS II patients are missing the enzyme iduronate sulfatase, which is essential to breaking down the mucopolysaccharides dermatan and heparan sulphate. These materials remain stored in the body's cells, causing progressive damage.
About Sangamo Therapeutics, Inc.
Established in 1995, Sangamo Therapeutics, Inc. is a clinical-stage biopharmaceutical company, focused on translating ground-breaking science into genomic therapies that transform patients' lives using the Company's industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company is headquartered in Richmond, California.
Last Close Stock Review
Sangamo Therapeutics' share price finished yesterday's trading session at $14.60, marginally sliding 0.34%. A total volume of 1.30 million shares have exchanged hands. The Company's stock price soared 47.47% in the last three months, 87.18% in the past six months, and 251.81% in the previous twelve months. Additionally, the stock skyrocketed 378.69% since the start of the year. The stock currently has a market cap of $1.22 billion.
Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (917) 341.4653
Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Pro-Trader Daily